INTRODUCTION AND OBJECTIVES:
The melanoma-associated antigen-A (MAGE-A) family is a highly attractive target for cancer immunotherapy because of its broad representation in cancer tissues but restricted expression in normal tissues. Recent studies have shown significant expression of MAGE A antigen in urothelial carcinoma (UC). We aim to assess MAGE A and Programmed Death-Ligand 1 (PD-L1) expression in a large UC cohort spanning multiple grades, stages, and including metastatic disease to inform immunotherapeutic approaches to the treatment of UC.
METHODS: Analysis of MAGE A and PD-L1 expression on neoplastic cells using immunohistochemical staining of tissue microarrays from patients with bladder cancer (T1-4, Nx, M0-1) was done using the H-score system (a measure that simultaneously accounts for frequency and intensity of expression). We compared differential expression as well as H-scores between superficial vs. invasive, low (LG) vs. high grade (HG) as well as localized (LO) (T1-2) vs. locally advanced (LA) (T3-4) and metastatic vs non-metastatic. Comparisons between groups were done using Student's T-test for continuous variables and Chi-Square for categorical variables.
RESULTS: There were a total of 443 cases, of which 40% stained positively for MAGE A. Furthermore, 26% of the cohort was > 50% positive for MAGE expression. Expression was positive in 36% of the LG vs. 64% of HG patients (p¼<0.001). Expression of MAGE was 48% in LO vs. 52% in LA (p¼0.02). Sub-stratifying by individual stage, pT2 had the highest expression (28%) and pT4 had the lowest (2%). Mean H-score for MAGE A between HG vs. LG was 59 vs. 30, respectively (p¼<0.001), Tis (15) vs. T1-4 (45) was also significant (p¼<0.001). LO vs. LA was not significant (p¼0.8), similarly metastatic vs. non-metastatic (p¼0.59). Mean H-score for PD-L1 was significantly higher in LA vs LO (26% vs. 10% p¼0.02), and in HG vs. LG (21% vs. 2% p¼<0.001). No significant difference was noted between metastatic vs. non-metastatic (p¼0.71). There was no significant correlation between MAGE and PD-L1 expression for HG (p¼0.08) or LA (p¼0.12).
CONCLUSIONS: This is the largest report of the expression of MAGE A antigen in urothelial carcinoma showing a significant expression in higher grade and stage urothelial carcinoma as well as significant proportion of patients with >50% positive expression. In conjunction with high PD-L1 expression in HG and LA these data support MAGE targeted immune interventions, including adoptive therapy with TCR engineered T cells for UC with or without combination with checkpoint inhibitor. METHODS: We identified 44 cases of MPUC that had tissue available for FISH and IHC at our institute, of which an NOS component sufficient for both FISH and IHC was identified in 37 cases. We followed the updated ASCO/CAP Guidelines for breast cancer and as such amplification was defined by a HER2/CEP17 ratio of 2.0 or > 6 copies of the gene and HER2 overexpression was considered with IHC scores of 2þ and 3þ.
RESULTS: In urothelial tumors with both MP and NOS components (n ¼ 37), ERBB2 amplification in MP and NOS components was present in 25 and 16 cases respectively. ERBB2 amplification was significantly higher in the MP component compared to NOS component within the same tumor (67.57% vs. 43.24%, p ¼ 0.049). HER2 overexpression in MP and NOS components was present in 25 and 13 cases respectively. HER2 overexpression was significantly higher in the MP component compared to NOS component within the same tumor (67.56% vs. 35.13%, p ¼ 0.012). In addition, ERBB2 amplification strongly correlated with HER2 overexpression in both MP (rho ¼ 0.65, p<0.001) and NOS (rho ¼ 0.74, p<0.001) components. In this cohort (n ¼ 44), tumor stage and lymph node status were significant predictors for overall survival (p ¼ 0.01, <0.001 respectively). However, ERBB2 amplification and HER2 overexpression in MP component were not associated with patients 0 survival outcome (p¼1.00, 0.75 respectively).
CONCLUSIONS: The majority of MPUC is associated with ERBB2 amplification and HER2 overexpression. In MPUC, ERBB2 amplification and HER2 overexpression were preferentially but not exclusively identified in MP component compared to NOS component. Our findings provide evidence for intratumoral heterogeneity of ERBB2 amplification and HER2 expression in MPUC. Vol. 197, No. 4S, Supplement, Sunday, May 14, 2017 THE JOURNAL OF UROLOGY â e637
